Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7377614 | 0.80 | L3MBTL1 (0.42) | TSHRCYP1A2NFKB1MAOAMAOB | |
| SCHEMBL168766 | 0.80 | — | — | |
| SCHEMBL2996071 | 0.78 | — | — | |
| SCHEMBL20901908 | 0.78 | — | — | |
| SCHEMBL29185897 | 0.78 | TSHR (0.37) | TSHRCYP1A2NFKB1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL2169126 | 0.78 | — | — | |
| SCHEMBL2746571 | 0.78 | — | — | |
| SCHEMBL28890203 | 0.77 | HIF1A (0.32) | TSHRCYP1A2NFKB1MAOAMAOB | |
| SCHEMBL11495937 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL1451885 | 0.75 | LMNA (0.40) | TSHRCYP1A2NFKB1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506154-B | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP | 2015-06-17 | — | — | CN | disclosed |
| US-20120095103-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8093425-B2 | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101506154-A | Compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| WO-2008136976-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-4904724-A | FREE RADICAL POLYMERIZATION OF CI-C20-ALKYL(METH)ACRYLATE AND UNSATURATED MONOMERS | BASF AKTIENGESELLSCHAFT (DE) | 1990-02-27 | — | — | US | disclosed |
| EP-0005051-B1 | 4-DESACETYL VLB C-3 CARBOXHYDRAZIDES, THEIR PREPARATION AND FORMULATIONS CONTAINING THEM | ELI LILLY AND COMPANY (US) | 1982-12-01 | — | — | EP | disclosed |
| EP-0005051-A1 | 4-Desacetyl VLB C-3 carboxhydrazides, their preparation and formulations containing them | ELI LILLY AND COMPANY (US) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095103-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | HSP90AB1, HSF1, HSP90B1 | TSHR 4361/4885CYP1A2 3740/4885NFKB1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.